DCLK1 Recombinant Monoclonal Antibody

說明書

中文名稱：

DCLK1 Recombinant Monoclonal Antibody
貨號：

CSB-RA033218A0HU
規格：

￥1320
圖片：
IHC image of CSB-RA033218A0HU diluted at 1:100 and staining in paraffin-embedded human small intestine tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.

Immunofluorescence staining of MCF-7 cell with CSB-RA033218A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Overlay Peak curve showing SH-SY5Y cells stained with CSB-RA033218A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for?10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

O15075
基因名：

DCLK1
別名：

Serine/threonine-protein kinase DCLK1 (EC 2.7.11.1) (Doublecortin domain-containing protein 3A) (Doublecortin-like and CAM kinase-like 1) (Doublecortin-like kinase 1), DCLK1, DCAMKL1 DCDC3A KIAA0369
反應種屬：

Human
免疫原：

A synthesized peptide from human DCLK1 protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

8B3
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, IF, FC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Probable kinase that may be involved in a calcium-signaling pathway controlling neuronal migration in the developing brain. May also participate in functions of the mature nervous system.
基因功能參考文獻：
1. DCLK1 plays an important role in cancer progression and is involved in the regulation of miR-200c expression. PMID: 29656186
2. The expression of DCLK1 was found in low-grade adenomas and increased with worsening severity of dysplasia. DCLK1 expression was highly observed in advanced adenomas, which had a clinically higher malignant potential. PMID: 29475922
3. High DCLK1 expression is associated with malignant pleural mesothelioma. PMID: 28560410
4. On the basis of these data, FOXD3 is a potent repressor of DCLK1-S expression in normal cells; loss of FOXD3 in hCCCs/hCRCs allows upregulation of DCLK1-S, imparting a potent invasive potential to the cells PMID: 28851816
5. Expression levels of phosphorylated cdc25A (p-cdc25A) and phosphorylated Chk1 (p-Chk1), belonging to the ATR pathway, were decreased by treatment with Dclk1 inhibitor LRRK2-IN-1 (LRRK), indicating Dclk1 involvement in the ATR pathway PMID: 29048622
6. In rectal cancer patients treated with preoperative chemoradiotherapy (CRT), DCLK1 expression was significantly correlated with lymph node metastasis and poor cancer-specific survival. However, in patients treated without preoperative therapy, no such correlation was found. DCLK1 expression can be associated with lymph node metastasis and poor cancer-specific survival in rectal cancer patients who receive CRT. PMID: 29924454
7. Pancreatic ductal adenocarcinoma patients with DCLK1-positive tumors had significantly shorter survival times than those with DCLK1-negative tumors. PMID: 28883702
8. DCLK1 plays crucial role in the regulation of epithelial-mesenchymal transition.DCLK1 is highly expressed in pancreatic neuroendocrine tumor. PMID: 28179411
9. DCLK1 is a prognostic biomarker for shortened survival. Secondly, through inhibition of DCLK1, it may serve as a therapeutic target as well PMID: 28351564
10. DCLK1 has been identified as a potential target for miR-448 to regulate lung squamous cell carcinoma cells growth. PMID: 28320089
11. Generated a (doublecortin like kinase 1) DCLK1-S-specific polyclonal antibody (S-isoform specific), and studied its use in screening of colon cancer after colonoscopy. PMID: 28414327
12. DCLK1 expression was observed in tumor cells in patients with pathological stage I non-small cell lung cancer (NSCLC)and was correlated with adverse prognosis, especially in patients with adenocarcinoma. DCLK1 may be a potential new therapeutic target PMID: 28382517
13. Biochemical and structural characterization of DCLK1 allowed for the mapping of cancer-causing mutations within the kinase domain. PMID: 27545623
14. Hence, we outline and discuss emerging evidence that strongly supports tuft cells as key regulatory cells in the complex network of the intestinal microenvironment. [review] PMID: 28684459
15. Our results indicate that Dclk1 is essential in advancing intestinal tumorigenesis. Knocking down Dclk1 decreases tumor stemness and progression and is thus predicted to regulate pro-survival signaling and tumor cell pluripotency. PMID: 28148261
16. The univariate and multivariate analyses suggested DCAMKL1 protein overexpression was an unfavorable prognostic factor in bladder cancer patients. In conclusion, DCAMKL1 is an independent poor prognostic factor for bladder cancer patients. PMID: 28621231
17. DCLK1 induction and its overexpression following hepatic injury are likely to contribute to tumorigenesis including maintenance and dissemination of tumor cells in circulation. PMID: 27694285
18. first evidence for the suppressive activity of miR-613 in hepatocellular carcinoma, which is causally linked to targeting of DCLK1 PMID: 27049311
19. MSX1 and DCLK1 might be used in colorectal cancer detection or as target of cancer therapies. PMID: 27966796
20. Increased expression of stromal DCLK1 was detected in endometriotic tissue compared to endometriosis patient endometrium. Stromal expression of DCLK1 was increased in endometrium of endometriosis patients compared to controls. PMID: 27881125
21. DCLK1 up-regulation may play a contributory role in colorectal cancer metastasis and poor prognosis via activation of EMT. DCLK1 may serve as an independent predictor for CRC prognosis. PMID: 27520310
22. Results showed the mechanism in which miR-137 regulates the expression of DCLK1, and demonstrated the opposite expression patterns of miR-137/DCLK1 in human non-small cell lung carcinoma and colon cancer stem cells. PMID: 26747706
23. DCLK1 promoter methylationis associated with lung cancer. PMID: 26311076
24. DCLK1 expression could aid in the prognostication and management of breast cancer with neuroendocrine differentiation. PMID: 26621833
25. DCLK1 controls these complex cellular signaling pathways to regulate hepatocellular carcinoma growth, and may be used as a prognostic biomarker. PMID: 26468984
26. results provide new insights into the molecular mechanism of the hepatitis B/C-virus induced liver inflammation and tumorigenesis via DCLK1-controlled networks PMID: 25948779
27. Data suggest that doublecortin and CaM kinase-like 1 protein short-transcripts (DCLK1-S) may represent an important target for preventing/inhibiting colon-cancers, and for eliminating colon-cancer-stem-cells (CSCs). PMID: 26447334
28. DCLK1 is essential for the invasive and metastatic properties of pancreatic cancer stem cells. PMID: 26764906
29. Data indicate that doublecortin-like kinase 1 (DCLK1) is overexpressed and has a unique methylation signature in renal clear cell carcinoma (RCC). PMID: 25605241
30. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PMID: 25723399
31. Increased expression of DCLK1 was observed in the epithelium, stroma and plasma of patients with Barrett's esophagus and esophageal adenocarcinoma. PMID: 25283374
32. Potential exist for DCLK1 as a colorectal cancer biomarker for early detection, but may also have clinical implications regarding the previously proposed therapy toward DCLK1-positive cancer cells. PMID: 24384857
33. XMD8-92 treatment results in inhibition of DCLK1 and downstream oncogenic pathways. PMID: 24880079
34. RNA interference-mediated silencing of DCLK1 triggers apoptotic cell death of colon cancer cells in vitro and in vivo. PMID: 24626093
35. DCLK1 mRNA levels were considerably reduced during FLV treatment. PMID: 24260365
36. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PMID: 24040120
37. Human pancreatic ductal adenocarcinoma cells contain morphologically and functionally distinct subpopulations, expressing DCLK1, that have cancer stem cell-like properties. PMID: 24096005
38. DCAMKL1 represses osteoblast activation by antagonizing Runx2, the master transcription factor in osteoblasts. PMID: 23918955
39. Dclk1 distinguishes between tumor and normal stem cells in the intestine. PMID: 23202126
40. DCAMKL-1 marks a subset of colorectal stem cells, as well as a subset of entero-endocrine cells. PMID: 22749579
41. the progressive increase of DCAMKL-1 expression in Barrett's esophagus from dysplasia to esophageal adenocarcinoma PMID: 21916995
42. Several DCLK1 variants were associated with disease phenotypes for rs7989807 in intron 3 (combination of SCZ, ADHD and BP), intron 19 (SCZ+BP) and the 3'UTR (SCZ+BP). PMID: 22539971
43. High DCAMKL1 is associated with HCV-induced hepatocarcinogenesis. PMID: 21937640
44. Eight suggestive significant loci were detected with a series of genes expressed within the inner ear that underlie the auditory function, such as: DCLK1, PTPRD, GRM8, CMIP. PMID: 21493956
45. Data show that siRNA-mediated knockdown of DCAMKL-1 in pancreatic cancer cells induced microRNA miR-200a, an EMT inhibitor, along with downregulation of EMT-associated transcription factors. PMID: 21285251
46. Together, our results suggest that silencing the DCLK splice variants DCL and DCLK-long induces apoptosis in NB cells. PMID: 20228126
47. genomic organization underlying the splice variants of DCLK and the expression profile of two splice variants affecting the kinase domain of DCLK and CPG16 (candidate plasticity gene 16). PMID: 11884394
48. high-quality wild-type crystals of doublecortin-like kinase were obtained and a complete native data set was collected to 1.5 A resolution PMID: 12595708
49. an examination of the binding sites on this protein PMID: 12692530
顯示更多

收起更多
蛋白家族：

Protein kinase superfamily, CAMK Ser/Thr protein kinase family, CaMK subfamily
組織特異性：

In fetal tissues, highly expressed in brain, detectable in lung and liver, but not in kidney. In adult tissues, expressed ubiquitously in the brain, detectable in the heart, liver, spleen, thymus, prostate, testis, ovary, small intestine and colon. The ty
數據庫鏈接：

HGNC: 2700

OMIM: 604742

KEGG: hsa:9201

STRING: 9606.ENSP00000255448

UniGene: Hs.507755

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDAC1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human, Mouse, Rat